Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - daratumumabum - concentrato per soluzione per infusione - daratumumabum 100 mg, histidinum, histidini hydrochloridum monohydricum, sorbitolum 273.3 mg, methioninum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 5 ml. - multipli myelom - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - daratumumabum - concentrato per soluzione per infusione - daratumumabum 400 mg, histidinum, histidini hydrochloridum monohydricum, sorbitolum 1093.0 mg, methioninum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 5 ml. - multipli myelom - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - daratumumabum - soluzione iniettabile - daratumumabum 1800 mg, hyaluronidasum humanum adnr, histidinum, histidini hydrochloridum monohydricum, sorbitolum 735.1 mg, methioninum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 15 ml. - multiples myelom, leichtketten-amyloidose - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ofatumumabum - konzentrat zur herstellung einer infusionslösung - ofatumumabum 100 mg, natrii acetas trihydricus, dinatrii edetas, polysorbatum 80, argininum, natrii chloridum, aqua ad iniectabilia q s. annuncio solutionem pro 5 ml. - behandlung der chronisch-lymphatischen leukämie - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ofatumumabum - konzentrat zur herstellung einer infusionslösung - ofatumumabum 1000 mg, natrii acetas trihydricus, dinatrii edetas, polysorbatum 80, argininum, natrii chloridum, aqua ad iniectabilia q s. annuncio solutionem pro 50 ml. - behandlung der chronisch-lymphatischen leukämie - biotechnologika

Unione Europea - italiano - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - mieloma multiplo - agenti antineoplastici - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

schering spa - indio (111in) satumomab pendetide - indio (111in) satumomab pendetide

Unione Europea - italiano - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - carfilzomibum - polvere per soluzione per infusione - praeparatio cryodesiccata: carfilzomibum 60 mg, sulfobutylbetadexum natricum 3000 mg, acidum citricum, natrii hydroxidum ad ph, nitrogenium, pro vitro corresp. natrium 216 mg. - onkologikum - synthetika